This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

Men in England diagnosed with incurable advanced prostate cancer are more likely to survive for at least three years than they were a decade ago, according to an analysis by the London School of Hygiene & Tropical Medicine (LSHTM) and partners.

The team studied data for 45,339 men who were newly diagnosed with metastatic prostate cancer, which is currently incurable, in England between 2015 and 2022, following each man for three years after diagnosis.

Although cases are rising overall, they found the proportion who died within three years fell from 56% in 2015 to 47% in 2022.

The prostate is a gland in the male reproductive system. Prostate cancer often grows slowly with no symptoms in the early stages. However, if it spreads to other parts of the body, such as the bones, it cannot be cured and may cause serious complications.

More men are living longer in part thanks to new treatments for this type of cancer being made available through the NHS.

The findings are published in the latest annual State of the Nation report from the National Prostate Cancer Audit, produced by the National Cancer Audit Collaborating Centre (NATCAN), based at the Clinical Effectiveness Unit, an academic partnership between LSHTM and the Royal College of Surgeons of England.

The report, which includes LSHTM staff among the authors, shows the number of men diagnosed with prostate cancer in England went up by 7% in a single year, to 60,800 in 2025, while the number of men diagnosed with metastatic disease, which has spread beyond the prostate, increased to more than 6,300.

Source link